biotech equivalent to microsoft, page-11

i forgot about this post of SoT's.. lol

but it is interesting to look at how far things have actually progressed on individual projects mentioned in the first post while the share price has declined 10% since the initial post 4 months ago.

It's good at highlighting how far management have pushed these projects despite no recognition in the value by market of progression.



1. Roche deal - transporting of macro-molecules into cells with the aid of a peptide carrier (cutting-edge).

= now extended & contract renegotiated to cross BBB



2. MRC Hutchison Research Centre (Cambridge University) collaboration - development of a revolutionary approach to cancer research. 'Protein Interference', would have wide application in the identification and validation of new drug targets.

= Phenomica spin-off ready to launch


3.CD40L internal program - next generation auto-immune disease treatment. The move from injectable meds to oral or nasel administration.

= Succesful collaborations validated & new partnerships formed with - Isogenica(UK) - XL-Proteing GmBH (Germany) - Pepscan Therapeutics (Netherlands)


4. Medimmune deal- finding peptide antibiotics to counter the worldwide rise of antibiotic resistent hospital acquired infections (superbugs)

= 12 month timeframe reaches end point in 1 month (August)


5. Pfizer deal - next generation vaccine program

= 6 months into 12 month contract